Narus Financial Partners LLC Sells 93 Shares of The Cigna Group (NYSE:CI)

Narus Financial Partners LLC lessened its stake in shares of The Cigna Group (NYSE:CI) by 6.3% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,382 shares of the health services provider’s stock after selling 93 shares during the period. Narus Financial Partners LLC’s holdings in The Cigna Group were worth $502,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of CI. Seizert Capital Partners LLC grew its holdings in shares of The Cigna Group by 195.8% during the fourth quarter. Seizert Capital Partners LLC now owns 32,150 shares of the health services provider’s stock valued at $9,627,000 after buying an additional 21,280 shares during the last quarter. Roman Butler Fullerton & Co. lifted its holdings in shares of The Cigna Group by 61.4% in the fourth quarter. Roman Butler Fullerton & Co. now owns 9,307 shares of the health services provider’s stock valued at $2,772,000 after purchasing an additional 3,539 shares in the last quarter. TFO Wealth Partners LLC grew its holdings in The Cigna Group by 98,980.0% during the fourth quarter. TFO Wealth Partners LLC now owns 4,954 shares of the health services provider’s stock worth $1,497,000 after buying an additional 4,949 shares in the last quarter. Ellsworth Advisors LLC purchased a new stake in The Cigna Group in the 4th quarter valued at $4,377,000. Finally, Sapient Capital LLC bought a new position in The Cigna Group during the 4th quarter valued at $2,811,000. 86.99% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have issued reports on CI. Oppenheimer upped their price objective on shares of The Cigna Group from $370.00 to $400.00 and gave the stock an “outperform” rating in a research report on Friday, May 3rd. StockNews.com downgraded shares of The Cigna Group from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, June 12th. Robert W. Baird began coverage on shares of The Cigna Group in a report on Thursday, May 30th. They issued an “outperform” rating and a $388.00 price target on the stock. Barclays began coverage on The Cigna Group in a research report on Wednesday, March 6th. They issued an “overweight” rating and a $393.00 target price for the company. Finally, Baird R W raised The Cigna Group to a “strong-buy” rating in a research report on Thursday, May 30th. Two analysts have rated the stock with a hold rating, fourteen have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $376.20.

Insider Buying and Selling

In other news, insider Brian C. Evanko sold 4,795 shares of The Cigna Group stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $345.01, for a total transaction of $1,654,322.95. Following the sale, the insider now owns 39,923 shares of the company’s stock, valued at approximately $13,773,834.23. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other The Cigna Group news, insider Brian C. Evanko sold 4,795 shares of the stock in a transaction on Monday, June 24th. The stock was sold at an average price of $345.01, for a total value of $1,654,322.95. Following the completion of the transaction, the insider now owns 39,923 shares in the company, valued at $13,773,834.23. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Elder Granger sold 1,000 shares of the business’s stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $338.08, for a total transaction of $338,080.00. Following the sale, the director now owns 5,471 shares in the company, valued at approximately $1,849,635.68. The disclosure for this sale can be found here. Insiders have sold 22,988 shares of company stock valued at $7,975,726 over the last ninety days. 0.70% of the stock is owned by insiders.

The Cigna Group Trading Down 0.3 %

CI traded down $1.11 on Tuesday, hitting $325.16. 381,006 shares of the company were exchanged, compared to its average volume of 1,610,939. The company has a debt-to-equity ratio of 0.75, a quick ratio of 0.71 and a current ratio of 0.71. The firm has a fifty day simple moving average of $341.23 and a two-hundred day simple moving average of $333.41. The stock has a market capitalization of $92.37 billion, a PE ratio of 26.72, a price-to-earnings-growth ratio of 1.01 and a beta of 0.52. The Cigna Group has a 12 month low of $253.95 and a 12 month high of $365.71.

The Cigna Group (NYSE:CI) last issued its earnings results on Thursday, May 2nd. The health services provider reported $6.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.17 by $0.30. The Cigna Group had a net margin of 1.76% and a return on equity of 17.24%. The firm had revenue of $57.25 billion for the quarter, compared to analysts’ expectations of $56.59 billion. During the same quarter last year, the business earned $5.41 earnings per share. The business’s revenue was up 23.2% on a year-over-year basis. Sell-side analysts expect that The Cigna Group will post 28.48 earnings per share for the current year.

The Cigna Group Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, June 20th. Stockholders of record on Tuesday, June 4th were issued a dividend of $1.40 per share. The ex-dividend date was Tuesday, June 4th. This represents a $5.60 dividend on an annualized basis and a dividend yield of 1.72%. The Cigna Group’s dividend payout ratio is currently 45.98%.

The Cigna Group Company Profile

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers.